🇺🇸 ADT in United States
71 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 71
Most-reported reactions
- Dizziness — 13 reports (18.31%)
- Nausea — 11 reports (15.49%)
- Palpitations — 9 reports (12.68%)
- Malaise — 8 reports (11.27%)
- Hypoaesthesia — 7 reports (9.86%)
- Diarrhoea — 6 reports (8.45%)
- Headache — 5 reports (7.04%)
- Cerebrovascular Accident — 4 reports (5.63%)
- Gamma-Glutamyltransferase Increased — 4 reports (5.63%)
- Malignant Neoplasm Progression — 4 reports (5.63%)
Other Oncology approved in United States
Frequently asked questions
Is ADT approved in United States?
ADT does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for ADT in United States?
Canadian Cancer Trials Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.